ACTA1 and Hepatic fibrosis: Treatment with JIB-04 clearly alleviated the symptoms of liver fibrosis, as demonstrated by a decrease in SR and α-SMA staining and a decrease in the infiltration of F4/80+ MACs (Fig. 6J).